Background
Methods
Search strategy and study selection
Criteria | Description |
---|---|
Study design | Studies with cross-sectional data or intervention data if the baseline data were available. |
Study participants | Studies were included if they recruited participants with KOA; where a control group was included, they had to be otherwise healthy and free from KOA. |
Study outcome domains | Studies had to include objective measures of foot mechanics or foot characteristics to be eligible. Objective measures of foot mechanics or characteristics included, but were not limited to, foot progression angle, rearfoot eversion, Foot Posture Index and muscle activity. Further data could be obtained from participants in a barefoot or shod condition, provided the shod condition was without any foot orthoses. |
Study results | Results had to provide quantitative data presented as mean and standard deviation or median and interquartile range clearly indicating if it was collected in a barefoot or shod condition. |
Data extraction
Assessment of study quality
Data analysis
Results
Study characteristics
No. | Author | Year published | Country | Subjects subgroups | No. of subjects (Men/ Women) | Age (years) | BMI (kg/m2) |
---|---|---|---|---|---|---|---|
1 | Abourazzak et al. [18] | 2014 | Morocco | KOA | 100 (21/79) | 59.68 ± 7.64 | 30.89 ± 4.94 |
Healthy control | 80 (20/60) | 48.66 ± 9.30 | 28.00 ± 3.81 | ||||
2 | Al-Zahrani and Bakheit [19] | 2002 | UK | KOA | 58 (14/44) | 71 ± 8.40 | NR |
Healthy control | 25 (10/15) | 69 ± 7.29 | NR | ||||
3 | Anan et al. [20] | 2015 | Japan | KOA | 20 (0/20) | 69 ± 4.4 | 24.4 ± 2.8 |
Healthy control | 17 (0/17) | 69.8 ± 4.3 | 21.3 ± 2.7 | ||||
4 | Arnold et al. [21] | 2014 | Australia | KOA | 15 (7/8) | 67.0 ± 8.9 | 30.7 ± 6.2 |
Healthy control | 15 (7/8) | 68.2 ± 9.7 | 25.5 ± 5.3 | ||||
5 | Bechard et al. [22] | 2012 | Canada | KOA | 20 (8/12) | 55 ± 8 | 28.9 ± 3.0 |
Healthy control | 20 (12/8) | 51 ± 8 | 25.9 ± 3.2 | ||||
6 | Booij et al. [23] | 2020 | Netherlands | Medial KOA only | 30 (14/16) | 62.7 ± 5.9 | 25.5 ± 2.7 |
7 | Butler et al. [24] | 2009 | USA | KOA only | 30 (13/17) | 63.1 ± 6.8 | 33.8 ± 6.9 |
8 | Butler et al. [25] | 2011 | USA | Medial KOA | 15 (NR/NR) | 66.2 ± 7.8 | 32.2 ± 7.9 |
Lateral KOA | 15 (NR/NR) | 65.3 ± 6.4 | 30.4 ± 7.5 | ||||
Healthy control | 15 (NR/NR) | 56.3 ± 10.7 | 27.8 ± 5.7 | ||||
9 | Chapman et al. [26] | 2015 | UK | KOA only | 70 (43/27) | 60.3 ± 9.6 | 30.5 ± ± 4.9 |
10 | Chang et al. [27] | 2007 | USA | KOA only | 56 (23/33) | 66.6 ± 8.6 | 29.0 ± 4.2 |
11 | Charlton et al. [28] | 2018 | Canada | Medial KOA only | 16 (6/10) | 67.4 ± 9.3 | 24.6 ± 15.1 |
12 | Elbaz et al. [29] | 2017 | Israel | KOA | 63 (22/41) | 64.2 ± 8.1 | NR |
Healthy control | 30 (21/9) | 67.9 ± 8.9 | NR | ||||
13 | Erhart-Hledik et al. [30] | 2017 | Canada | Medial KOA only | 10 (9/1) | 65.3 ± 9.8 | 27.8 ± 3.0 |
14 | Gardner et al. [31] | 2015 | USA | KOA | 13 (NR/NR) | 56.8 ± 5.2 | 26.6 ± 3.6 |
Healthy control | 11 (NR/NR) | 50.0 ± 9.7 | 25.9 ± 5.4 | ||||
15 | Guler et al. [32] | 2009 | Turkey | KOA only | 115 (0/115) | 62.11 ± 8.72 | 32.91 ± 4.14 |
16 | Guo et al. [33] | 2007 | USA | KOA only | 10 (6/4) | 64 ± 8 | 29.0 ± 5.6 |
17 | Hinman et al. [34] | 2012 | Australia | KOA only | 73 (28/45) | 63.3 ± 8.4 | 27.7 ± 3.6 |
18 | Hinman et al., [35] | 2016 | Australia | KOA only | 81 (39/42) | 63.3 ± 7.9 | 29.7 ± 3.7 |
19 | Khan et al. [36] | 2019 | Malaysia | KOA only | 20 (NR) | 61.5 ± 8.63 | NR |
20 | Krackow et al. [37] | 2011 | USA | KOA | 8 (4/4) | 59 ± 11.34 | 33.84 ± 6.90 |
Healthy control | 10 (5/5) | 62.50 ± 4.17 | 28.44 ± 4.23 | ||||
21 | Levinger et al. [38] | 2010 | Australia | KOA | 32 (16/16) | 65.84 ± 7.57 | 29.97 ± 5.26 |
Healthy control | 28 (13/15) | 65.22 ± 11.41 | 25.56 ± 3.95 | ||||
22 | Levinger et al. [39] | 2012a | Australia | KOA | 50 (27/23) | 66.4 ± 7.6 | 29.6 ± 5.1 |
Healthy control | 28 (13/15) | 65.1 ± 11.2 | 25.7 ± 3.9 | ||||
23 | Levinger et al. [40] | 2012b | Australia | KOA | 32 (16/16) | 65.8 ± 7.5 | 29.9 ± 5.2 |
Healthy control | 28 (13/15) | 65.2 ± 11.4 | 25.5 ± 3.9 | ||||
24 | Lidtke et al. [41] | 2010 | USA | KOA | 25 (6/19) | 60.2 ± 10.6 | 29.2 ± 4.6 |
Healthy control | 25 (12/13) | 58.5 ± 9.1 | 26.6 ± 3.3 | ||||
25 | Nigg et al. [42] | 2006 | Canada | KOA only | 123 (56/67) | 57.4 ± 2.2 | 29.5 ± 1.6 |
26 | Ohi et al. [43] | 2017 | Japan | KOA only | 88 (30/58) | 74.8 ± 7.58 | 24.3 ± 3.54 |
27 | Paquette et al. [44] | 2015 | USA | KOA | 13 (6/7) | 62.5 ± 9 | 28.3 ± 6.5 |
Healthy control | 13 (5/8) | 58.9 ± 8.3 | 23.9 ± 2.6 | ||||
28 | Park et al. [45] | 2016 | Canada | KOA | 24 (7/17) | 54 ± 7.3 | 26.1 ± 3.4 |
Healthy control | 24 (8/16) | 52.4 ± 10.6 | 24.7 ± 3.2 | ||||
29 | Reilly et al. [46] | 2006 | UK | KOA | 60 (25/35) | 67.80 ± 8.09 | NR |
Healthy control | 60 (28/32) | 64.92 ± 12.18 | NR | ||||
30 | Reilly et al. [47] | 2009 | UK | Medial KOA | 20 (9/11) | 63 ± 8.7 | NR |
Healthy control | 20 (4/16) | 56 ± 7.3 | NR | ||||
31 | Rutherford et al. [48] | 2008 | Canada | KOA asymptomatic | 50 (32/18) | 53 ± 10 | 26 ± 4 |
KOA mild to moderate | 46 (20/26) | 60 ± 9 | 31 ± 5 | ||||
KOA severe | 44 (20/24) | 67 ± 8 | 32 ± 5 | ||||
32 | Rutherford et al. [49] | 2010 | Canada | KOA | 17 (10/7) | 56 ± 8.8 | 29.8 ± 6.5 |
Healthy control | 20 (7/13) | 46.5 ± 7.0 | 25.9 ± 4.8 | ||||
33 | Saito et al. [50] | 2013 | Japan | KOA | 50 (10/40) | 75 | NR |
Elderly control | 44 (8/36) | 74 | NR | ||||
34 | Shakoor et al. [51] | 2008 | USA | KOA | 27 (5/22) | 54 ± 12 | 37.8 ± 8.6 |
Healthy control | 14 (5/9) | 47 ± 14 | 29.8 ± 5.6 | ||||
35 | Simic et al. [52] | 2013 | Australia | KOA only | 22 (9/13) | 69.7 ± 9.0 | 28.4 ± 4.8 |
36 | Tan et al. [53] | 2020 | Australia | KOA only | 21 (7/14) | 58 ± 8 | 27.0 ± 4.8 |
37 | Trombini-Souza et al. [54] | 2011 | Brazil | KOA | 21 (0/21) | 6 5 ± 5 | NR |
Healthy control | 24 (0/24) | 65 ± 4 | NR | ||||
38 | Van Tunen et al. [55] | 2018 | Australia | Medial KOA only | 21 (9/12) | 63.4 ± 7.0 | 29.8 ± 3.6 |
39 | Zhang et al. [56] | 2017 | China | KOA | 23 (0/23) | 64.2 ± 6.6 | 23.3 ± 1.9 |
Healthy control | 23 (0/23) | 62.1 ± 2.4 | 22.6 ± 1.8 |
Participant characteristics
Participant age
Body mass index
Participant eligibility criteria
Assessment of study quality
Item Number | Recommendations | Abourazzak et al., 2014 [18] | Al-zahrani amd Bakheit, 2002 [19] | Anan et al., 2015 [20] | Arnold et al., 2014 [21] | Bechard et al., 2012 [22] | Booij et al., 2020 [23] | Butler et al., 2009 [24] | Butler et al., 2011 [25] | Charlton et al. 2018 [28] | Chang et al., 2007 [27] | Chapman et al., 2015 [26] | Elbaz et al., 2017 [29] | Erhart-Hledik et al., 2017 [30] | Gardner et al., 2015 [31] | Guler et al., 2009 [32] | Guo et al., 2007 [33] | Hinman et al., 2012 [34] | Hinman et al., 2016 [35] | Khan et al., 2019 [36] | Krackow et al., 2011 [37] |
1a | Abstract: study’s design in the title or the abstract | No | No | No | Yes | No | No | No | Yes | No | No | No | No | No | No | No | No | No | Yes | Yes | No |
1b | Abstract: balanced summary | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
2 | Introduction: background and rationale | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
3 | Introduction: objectives, including hypotheses | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
4 | Methods: study design early in the paper | Yes | No | No | Yes | No | Yes | No | Yes | No | No | No | Yes | Yes | No | No | No | No | Yes | Yes | No |
5 | Methods: setting, locations, and relevant dates, recruitment, data collection | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
6a | Methods: cohort eligibility criteria, follow-up | NA | NA | NA | NA | NA | NA | NA | NA | NA | Yes | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
6a | Methods: case-control: eligibility criteria of cases and controls | Yes | Yes | Yes | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
6a | Methods: cross-sectional: eligibility criteria and methods of participants’ selection | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
6b | Methods: cohort: number of exposed and unexposed | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | Yes | NA | NA |
6b | Methods: case-control: matching criteria | Yes | Yes | Yes | NA | Yes | NA | NA | NA | NA | NA | NA | Yes | NA | Yes | NA | NA | NA | NA | NA | NA |
7 | Methods: define outcomes, exposures, diagnostic criteria | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
8 | Methods: sources of data, methods of assessment (measurement) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
9 | Methods: how bias addressed | No | No | No | No | No | No | No | No | No | Yes | Yes | No | No | No | No | No | No | Yes | Yes | No |
10 | Methods: power analysis | No | No | No | No | Yes | No | Yes | Yes | No | No | No | No | Yes | No | No | No | No | No | Yes | No |
11 | Methods: quantitative variables addressed | Yes | No | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
12a | Methods: statistical methods | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
12b | Methods: statistical subgroups and interactions | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | NA | Yes | Yes | Yes |
12c | Methods: how missing data addressed | NA | No | NA | No | No | No | NA | No | No | No | No | No | No | No | No | No | No | Yes | No | No |
12d | Methods: cohort: how loss to follow-up addressed | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
12d | Methods: case-control: how matching of cases and controls addressed | No | No | No | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | Yes | NA | NA |
12d | Methods: cross-sectional: sampling strategy | NA | NA | NA | Yes | No | No | Yes | Yes | No | NA | Yes | Yes | No | No | No | Yes | No | NA | No | No |
12e | Methods: sensitivity analyses | No | No | No | Yes | No | Yes | No | Yes | No | No | No | No | No | No | No | No | No | Yes | No | No |
13a | Results: numbers of individuals at each stage | Yes | No | Yes | Yes | Yes | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes |
13b | Results: reasons for non-participation at each stage | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | Yes | No | No |
13c | Results: use of a flow diagram | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | Yes | No | No |
14a | Results: characteristics of study participants | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
14b | Results: number with missing data | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | Yes | No | No |
14c | Results: cohort: follow-up time | NA | NA | NA | NA | NA | NA | NA | NA | NA | Yes | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
15 | Results: cohort: summary measures over time | NA | NA | NA | NA | NA | NA | NA | NA | NA | Yes | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
15 | Results: case-control: summary measures of exposure | Yes | Yes | Yes | NA | NA | NA | NA | NA | NA | NA | NA | No | NA | NA | NA | NA | NA | Yes | NA | NA |
15 | Results: cross-sectional: numbers of events or measures | NA | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes | Yes |
16a | Results: unadjusted estimates | Yes | No | Yes | Yes | Yes | No | Yes | Yes | No | Yes | No | Yes | Yes | Yes | Yes | No | Yes | No | No | Yes |
16b | Results: category boundaries | Yes | No | No | No | No | No | No | No | No | Yes | Yes | No | No | No | No | No | No | NA | No | No |
16c | Results: translating relative risk into absolute risk | NA | No | No | Yes | No | NA | No | No | No | No | No | NA | No | NA | NA | No | No | NA | No | No |
17 | Results: other analyses (subgroups and interactions, and sensitivity) | Yes | No | No | No | No | No | No | No | No | Yes | No | Yes | No | Yes | No | No | Yes | Yes | No | Yes |
18 | Discussion: summarise key results with reference to study objectives | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
19 | Discussion: limitations | No | No | Yes | Yes | No | Yes | No | Yes | Yes | No | Yes | Yes | No | Yes | No | No | Yes | Yes | Yes | Yes |
20 | Discussion: overall interpretation of results considering other relevant evidence | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
21 | Discussion: generalisability of results | No | No | No | Yes | No | No | No | No | No | No | No | No | No | No | No | Yes | Yes | Yes | No | No |
22 | Funding: source of funding | No | No | No | No | Yes | Yes | No | Yes | Yes | Yes | Yes | No | Yes | Yes | No | No | Yes | Yes | Yes | No |
% | Total percentage of successfully reported criteria in each study | 61 | 42 | 58 | 72 | 58 | 58 | 53 | 72 | 50 | 66 | 63 | 64 | 59 | 63 | 48 | 53 | 61 | 94 | 61 | 56 |
Item Number | Recommendations | Levinger et al., 2010 [38] | Levinger et al., 2012a [39] | Levinger et al., 2012 [40] | Lidtke et al., 2010 [41] | Nigg et al., 2006 [42] | Ohi et al., 2017 [43] | Paquette et al., 2015 [44] | Park et al., 2016 [45] | Reilly et al., 2006 [46] | Reilly et al., 2009 [47] | Rutherford et al., 2008 [48] | Rutherford et al., 2010 [49] | Saito et al., 2013 [50] | Shakoor et al., 2008 [51] | Simic et al., 2013 [52] | Tan et al., 2020 [53] | Trombini-Souza et al., 2011 [54] | Van Tunen et al., 2018 [55] | Zhang et al., 2017 [56] | |
1a | Abstract: study’s design in the title or the abstract | No | No | No | No | Yes | No | No | No | No | Yes | Yes | No | No | No | No | No | No | Yes | No | |
1b | Abstract: balanced summary | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
2 | Introduction: background and rationale | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
3 | Introduction: objectives, including hypotheses | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
4 | Methods: study design early in the paper | No | No | No | No | Yes | Yes | No | No | Yes | Yes | Yes | No | No | Yes | No | Yes | No | Yes | No | |
5 | Methods: setting, locations, and relevant dates, recruitment, data collection | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
6a | Methods: cohort eligibility criteria, follow-up | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
6a | Methods: case-control: eligibility criteria of cases and controls | NA | Yes | Yes | Yes | NA | NA | NA | NA | Yes | NA | NA | NA | NA | NA | NA | NA | NA | NA | Yes | |
6a | Methods: cross-sectional: eligibility criteria and methods of participants’ selection | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | NA | |
6b | Methods: cohort: number of exposed and unexposed | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
6b | Methods: case-control: matching criteria | Yes | Yes | Yes | Yes | NA | NA | Yes | Yes | Yes | NA | NA | Yes | Yes | NA | NA | NA | NA | NA | Yes | |
7 | Methods: define outcomes, exposures, diagnostic criteria | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | |
8 | Methods: sources of data, methods of assessment (measurement) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
9 | Methods: how bias addressed | No | No | No | No | No | Yes | No | No | No | Yes | No | No | No | No | No | No | No | No | No | |
10 | Methods: power analysis | No | No | No | No | Yes | No | Yes | No | Yes | Yes | No | No | No | No | Yes | Yes | Yes | No | No | |
11 | Methods: quantitative variables addressed | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | |
12a | Methods: statistical methods | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
12b | Methods: statistical subgroups and interactions | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes | Yes | Yes | Yes | |
12c | Methods: how missing data addressed | No | No | No | No | Yes | No | No | No | No | No | No | No | No | No | No | No | No | No | No | |
12d | Methods: cohort: how loss to follow-up addressed | NA | NA | NA | NA | Yes | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
12d | Methods: case-control: how matching of cases and controls addressed | NA | No | No | No | NA | NA | No | No | No | NA | NA | No | No | NA | NA | NA | NA | NA | No | |
12d | Methods: cross-sectional: sampling strategy | Yes | Yes | Yes | Yes | Yes | No | Yes | NA | NA | Yes | No | NA | NA | No | NA | Yes | No | No | NA | |
12e | Methods: sensitivity analyses | No | No | No | No | No | Yes | Yes | No | Yes | Yes | No | No | No | No | No | Yes | No | Yes | No | |
13a | Results: numbers of individuals at each stage | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | |
13b | Results: reasons for non-participation at each stage | No | No | No | No | Yes | Yes | No | No | No | No | No | No | No | No | No | No | No | No | No | |
13c | Results: use of a flow diagram | No | No | No | No | Yes | Yes | No | No | No | No | No | No | No | No | No | No | No | No | No | |
14a | Results: characteristics of study participants | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
14b | Results: number with missing data | No | No | No | No | Yes | Yes | No | No | No | No | No | No | No | No | No | No | No | No | No | |
14c | Results: cohort: follow-up time | NA | NA | NA | NA | Yes | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
15 | Results: cohort: summary measures over time | NA | NA | NA | NA | Yes | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
15 | Results: case-control: summary measures of exposure | NA | NA | NA | NA | NA | NA | No | Yes | Yes | NA | NA | NA | NA | NA | NA | NA | NA | NA | Yes | |
15 | Results: cross-sectional: numbers of events or measures | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | NA | |
16a | Results: unadjusted estimates | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | No | Yes | Yes | Yes | No | Yes | Yes | Yes | No | Yes | No | |
16b | Results: category boundaries | No | No | Yes | No | Yes | No | Yes | No | No | Yes | No | No | No | No | No | No | No | No | No | |
16c | Results: translating relative risk into absolute risk | NA | No | No | NA | No | NA | No | NA | No | No | No | No | No | No | No | No | No | No | No | |
17 | Results: other analyses (subgroups and interactions, and sensitivity) | No | No | No | No | Yes | Yes | No | No | Yes | Yes | Yes | NA | No | Yes | No | No | No | Yes | No | |
18 | Discussion: summarise key results with reference to study objectives | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
19 | Discussion: limitations | No | Yes | Yes | Yes | No | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Yes | No | |
20 | Discussion: overall interpretation of results considering other relevant evidence | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
21 | Discussion: generalisability of results | No | No | No | No | Yes | Yes | Yes | No | Yes | Yes | No | No | No | No | No | No | No | Yes | Yes | |
22 | Funding: source of funding | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | |
% | Total percentage of successfully reported criteria in each study | 56 | 60 | 63 | 62 | 83 | 84 | 69 | 58 | 61 | 81 | 63 | 63 | 52 | 63 | 60 | 69 | 50 | 69 | 48 |
Outcomes measures
Foot variables | Study, year | Instrument- Shod condition | Results | P-value | |
---|---|---|---|---|---|
KOA | Controls | ||||
Foot Progression Angle or toe-out degree (0) | Bechard et al., 2012 | 3D motion analysis system, force platform- Wearing lab shoes | 6.2 ± 6.1 | 9.4 ± 5.0 | 0.68 |
Booij et al., 2020 | 3D motion analysis system, force platform- Barefoot | −40.12 ± 4.80 | No controls | NA | |
Chang et al., 2007 | 3D motion analysis system, force platform- Barefoot | 18.1 ± 8.4 | No controls | NA | |
Guo et al., 2007 | 3D motion analysis system, force platform- Wearing lab shoes | 2.0 ± 6.8 | No controls | NA | |
Hinman et al., 2012 | 3D motion analysis system, force platform- Wearing lab shoes | −6.06 ± 5.56 | No controls | NA | |
Khan et al., 2019 | 3D motion analysis system, force platform- Barefoot | 9.6 ± 3.7 | No controls | NA | |
Krackow et al., 2011 | 3D motion analysis system, force platform- Barefoot | 8.58 ± 2.37 | 15.36 ± 2.12 | NR | |
Paquette et al., 2015 | 3D motion analysis system, force platform- Barefoot | 13 ± 4 | 12.2 ± 3.5 | 0.82 | |
Rutherford et al., 2008 | 3D motion analysis system, force platform- Barefoot | 7.5 ± 5 | 7.3 ± 5 | NA | |
Rutherford et al., 2010 | 3D motion analysis system, force platform- Barefoot | 6.6 ± 7.3 | 4.9 ± 4.7 | 0.625 | |
Simic et al., 2013 | 3D motion analysis system- Wearing lab shoes | −4.5 ± 1.5 | No controls | NA | |
Trombini-Souza et al., 2011 | 3D motion analysis system, force platform- Barefoot | 12.2 ± 6.74 | 13.1 ± 7.90 | 0.71 | |
Peak rearfoot eversion (0) | Arnold et al., 2014 | 3D motion analysis system, force platform – Barefoot | 5.3 ± 4.2 | 4.5 ± 5.0 | 0.850 |
Butler et al., 2009 | 3D motion analysis system, force platform- Wearing lab shoes | 3.5 ± 4.3 | No controls | NA | |
Butler et al., 2011 | 3D motion analysis system, force platform- Wearing lab shoes | 6.2 ± 5.0 | 3.5 ± 2.7 | 0.01* | |
Chapman et al., 2015 | 3D motion analysis system, force platform- Wearing lab shoes | 3.51 ± 2.77 | No controls | NA | |
Erhart-Hledik et al., 2017 | 3D motion analysis system, force platform- Wearing lab shoes | 13.9 ± 5.4 | No controls | NA | |
Levinger et al., 2012 | 3D motion analysis system, force platform- Barefoot | 1.3 ± 5.2 | 2.3 ± 3.9 | NR | |
Nigg et al., 2006 | Biodex system- Wearing lab shoes | 41.9 | No controls | NA | |
Peak rearfoot inversion (0) | Arnold et al., 2014 | 3D motion analysis system, force platform- Barefoot | 1.4 ± 4.4 | 1.1 ± 4.2 | 0.708 |
Levinger et al., 2012 | 3D motion analysis system, force platform- Barefoot | 11.6 ± 5.2 | 14.9 ± 5.0 | NR | |
Nigg et al., 2006 | Biodex system- Wearing lab shoes | 45.1 | No controls | NA | |
Pes planus prevalence (%) | Abourazzak et al., 2014 | Visual observation (FPI)- Barefoot | 42 | 22 | 0.03* |
Guler et al., 2009 | Objective manual testing- Barefoot | 38.3 | No controls | NA | |
Foot pronation (difference in FPI) | Abourazzak et al., 2014 | Visual observation (FPI)- Barefoot | 1.5 ± 2.68 | 0.72 ± 2.63 | 0.05* |
Levinger et al., 2010 | Visual observation (FPI)- Barefoot | 2.46 ± 2.18 | 1.35 ± 1.43 | 0.022* |
Study, year of publish | Foot variable (outcome) | Instrument- Shod condition | Results | P-value | |
---|---|---|---|---|---|
KOA | Controls | ||||
Abourazzak et al., 2014 [18] | Prevalence of pes cavus (%) | Visual observation (FPI)- Barefoot | 58 | 77 | 0.004* |
Elbaz et al., 2017 [29] | Achilles tendon thickness (mm) | Digital caliper- Barefoot | 17.1 ± 3.4 | 15.1 ± 3.1 | 0.009 |
Guler et al., 2009 [32] | Hallux valgus deformity (%) | Objective manual testing, radiography (x-ray)- Barefoot | 22.60 | No controls | NA |
Hinman et al., 2016 [35] | FPI (n, %) | Visual observation (FPI)- Barefoot | |||
Severely supinated | 1 (1) | No controls | NA | ||
Supinated | 0 (0) | ||||
Normal | 44 (54) | ||||
Pronated | 30 (37) | ||||
Severely pronated | 6 (7) | ||||
Levinger et al., 2010 [38] | Vertical navicular height | Objective manual testing, static footprint- Barefoot | 0.23 ± 0.03 | 0.24 ± 0.03 | 0.542 |
Navicular drop | 0.02 ± 0.01 | 0.03 ± 0.01 | 0.019* | ||
Arch index | 0.26 ± 0.04 | 0.22 ± 0.04 | 0.04* | ||
Ohi et al., 2017 [43] | Hallux valgus angle (°) | 3D footprint automatic (laser) measurement- Barefoot | 13.6 ± 7.22 | No controls | NA |
Presence of hallux valgus (%) | 12.5 | ||||
Navicular height (mm) | 30.1 ± 6.75 | ||||
Calcaneus angle relative to floor (°) | 1.35 ± 5.09 | ||||
Rear foot angle (°) | 6.01 ± 3.76 | ||||
Reilly et al., 2006 [46] | Navicular height in sitting (cm) | Objective manual testing (goniometer)- Barefoot | 5.22 ± 0.94 | 5.28 ± 0.89 | 0.005* |
Navicular height in standing (cm) | 4.69 ± 0.83 | 4.73 ± 0.98 | 0.003* | ||
Reilly et al., 2009 [47] | FPI** | Visual observation (FPI)- Barefoot | 7.0 (−2 to 10)** | 1.0 (−4 to 8)** | < 0.001* |
Ankle dorsiflexion during sitting (°)** | Objective manual testing using goniometer -Barefoot | 9.0 (0 to 32)** | 7.5 (0 to 15)** | < 0.001* | |
Shakoor et al., 2008 [51] | VPT (volts) | Biothesiometer, AP radiography- Barefoot | |||
First MTPJ | 15 ± 9.9 | 6.4 ± 3.3 | < 0.001* | ||
Medial malleolus | 22 ± 11.7 | 12.3 ± 5.2 | 0.001* | ||
Lateral malleolus | 22.3 ± 10.5 | 10.4 ± 3.2 | < 0.001* | ||
Tan et al., 2020 [53] | FPI | Visual observation (FPI)- Midfoot and arch height mobility/arch indices- Barefoot | 3 (1 to 7) | No controls | NA |
Arch height difference (mm) | 8.8 ± 5.2 | ||||
Midfoot width difference (mm) | 8.9 ± 3.1 | ||||
Foot mobility magnitude (mm) | 14.8 ± 7.9 | ||||
Van Tunen et al., 2018 [55] | FPI (n, %) | Visual observation (FPI)- Barefoot Foot mobility magnitude calculation Navicular drop test | |||
Normal (scores 0 to + 5) | 9 (43) | No controls | NA | ||
Pronated (scores + 6 to + 9) | 11 (52) | ||||
Highly pronated (scores greater + 9) | 1 (5) | ||||
Foot mobility magnitude (mm) | 9.6 ± 3.8 | ||||
Navicular drop (mm) | 7.6 ± 3.1 |
Study, year of publish | Foot variable (outcome) | Instrument- Shod condition | Results | P-value | |
---|---|---|---|---|---|
KOA | Controls | ||||
Al-Zahrani and Bakheit 2002 [19] | Ankle plantar flexion in stance (°)** | 3D motion analysis system, force platform- Barefoot | 19.01 (15.90 to 22.70)** | 30.88 (23.50 to 35.60)** | < 0.12 |
Ankle plantar flexion in swing (°)** | 27.76 (17.70 to 26.40)** | 22.74 (15.90 to 22.70)** | < 0.02* | ||
Ankle moment (pre-swing) (Nm/kg)** | 0.57 (0.36 to 0.78)** | 0.79 (0.61 to 0.91)** | < 0.002* | ||
Ankle power (pre-swing) (Watt/k.)** | 1.46 (0.53 to 2.31)** | 3.86 (2.91 to 4.58)** | < 0.000* | ||
Anan et al., 2015 [20] | Maximum ankle plantar flexion moment during STS (Nm/kg) | 3D motion analysis system, force platform- Barefoot | 0.36 ± 0.07 | 0.34 ± 0.07 | 0.343 |
Mean ankle plantar flexion moment during STS (Nm/kg) | 0.23 ± 0.06 | 0.24 ± 0.08 | 0.685 | ||
Ankle planter flexion moment impulse during STS (Nms/kg) | 0.47 ± 0.16 | 0.38 ± 0.15 | 0.072 | ||
Arnold et al., 2014 [21] | Hindfoot conronal plane ROM (o) | 3D motion analysis system, force platform- Barefoot | 10.9 ± 3.4 | 10.9 ± 4.3 | 0.562 |
Butler et al., 2009 [24] | Rearfoot eversion excursion (o) | 3D motion analysis system, force platform- Wearing lab shoes | 10.1 ± 2.8 | No controls | NA |
−0.030 ± 0.034 | |||||
Peak rearfoot eversion moment (Nm/kg*m) | |||||
Butler et al., 2011 [25] | Peak rearfoot inversion moment (Nm/kg*m) | 3D motion analysis system, force platform- Wearing lab shoes | −0.050 ± | − 0.062 ± | 0.38 |
Rearfoot eversion excursion (o) | 0.045 | 0.03 | 0.96 | ||
10.6 ± 5.6 | 10.2 ± 3.7 | ||||
Charlton et al. 2018 [28] | Foot rotation angle during natural walking: | 3D motion analysis system- Barefoot | |||
Ipsilateral foot (°) | −7.8 ± 7.9 | No controls | NA | ||
Contralateral foot (°) | −8.4 ± 5.7 | ||||
Gardner et al., 2007 [31] | Planter flexion angle during cycling (o) | 3D motion analysis system, force platform- Wearing lab shoes | −6.0 ± 8.5 | − 8.9 ± 10.7 | 0.834 |
Ankle eversion during cycling (o) | −6.8 ± 8.5 | −13.2 ± 8.4 | 0.015* | ||
Internal rotation angle (o) | 8.1 ± 7.1 | 9.2 ± 7.6 | 0.849 | ||
Guo et al., 2007 [33] | FPA during stair ascent (o) | 3D motion analysis system, force platform- Wearing lab shoes | 2.5 ± 6.6 | No controls | NA |
FPA during stair descent (o) | 11.3 ± 8.9 | ||||
Hinman et al., 2012 [34] | COP offset (mm) | 3D motion analysis system, force platform- Wearing lab shoes | −5.6 ± 4.3 | No controls | NA |
Levinger et al.,2012a [39] | Ankle dorsiflexion (o) | 3D motion analysis system, force platform-Barefoot | 3.6 ± 3.3 | 2.4 ± 2.8 | 0.08 |
Ankle adduction (0) | 2.8 ± 1.9 | 4.2 ± 2.1 | 0.01* | ||
Toe clearance sensitivity in ankle (mm/degrees) | −0.1 ± 3.5 | 1.1 ± 4.5 | 0.05* | ||
Levinger et al., 2012b [40] | Rearfoot frontal plane ROM (o) | 3D motion analysis system, force platform- Barefoot | 10.2 ± 3.3 | 12.5 ± 3.1 | NR |
Rearfoot transverse plane ROM (o) | 8.8 ± 4.7 | 10.0 ± 4.9 | NR | ||
Internal rotation (o) | 11.7 ± 6.3 | 15.4 ± 7.9 | NR | ||
External rotation (o) | 2.9 ± 5.8 | 5.4 ± 6.1 | NR | ||
Lidtke et al., 2010 [41] | COP index | Plantar pressure plate- Barefoot | −5.87 ± 5.6 | −0.45 ± 3.45 | < 0.001* |
Nigg et al., 2006 [42] | Ankle plantar flexion (o) | Biodex system- Wearing lab shoes | 50.6 | No controls | NA |
Ankle dorsiflexion (o) | 22.2 | ||||
Park et al., 2016 [45] | MVIC of ankle inversion muscle group (N/kg) | Force dynamometer- Wearing lab shoes | 0.62 ± 0.26 | 0.86 ± 0.31 | 0.007* |
Reilly et al., 2006 [46] | Ankle Plantar flexion in sitting (°) | Objective manual testing (goniometer)- Barefoot | 50.72 ± 11.49 | 52.13 ± 10.94 | 0.788 |
Ankle dorsiflexion in sitting (°) | 10.07 ± 4.29 | 8.4 ± 3.71 | 0.000* | ||
Calcaneal angle in sitting (°) | 2.02 ± 2.04 | −0.25 ± 2.93 | 0.000* | ||
Saito et al., 2013 [50] | Partial foot pressure per body weight (%) | Plantar pressure sensor insoles during walking- Wearing lab shoes | |||
Heel | 27.1 ± 11.2 | 41.7 ± 8.5 | < 0.001* | ||
Central | 33.1 ± 11.2 | 16.5 ± 13.8 | < 0.001* | ||
Metatarsal | 12.4 ± 7.9 | 12.1 ± 6.7 | > 0.001 | ||
Hallux | 1.5 ± 2.2 | 3.5 ± 3.0 | < 0.001* | ||
Lateral toes | 1.2 ± 1.7 | 2.5 ± 2.1 | > 0.001 | ||
Tan et al., 2020 [53] | Peak dorsiflexion angle in stance (°) during walking | 3D motion analysis system, force platform-Wearing lab shoes | 14.9 ± 3.2 | No controls | NA |
Peak dorsiflexion moment (Nm/kg) during walking | 0.15 ± 0.27 | ||||
Peak dorsiflexion angle in stance (°) stair ascent / descent. | 9.7 ± 4.4 | ||||
Peak dorsiflexion moment (Nm/kg) stair ascent / descent. | 1.08 ± 0.22 | ||||
Weight bearing ankle joint dorsiflexion ROM (cm) | Knee to wall test | 9.1 ± 3.2 | |||
Zhang et al., 2017 [56] | Contact area (cm2) | Plantar pressure sensor insoles during walking- Wearing lab shoes | |||
Heel | 28.9 ± 2.9 | 28.6 ± 1.7 | 0.982 | ||
Midfoot | 41.5 ± 5.8 | 36.5 ± 7.3 | 0.043* | ||
1st MTPJ | 13.8 ± 1.6 | 13.1 ± 1.3 | 0.875 | ||
2nd MTPJ | 13.6 ± 0.8 | 13.2 ± 1.3 | 0.922 | ||
3rd-5th MTPJ | 12.7 ± 0.6 | 12.8 ± 0.3 | 0.986 | ||
Hallux | 7.1 ± 1.7 | 6.6 ± 1.6 | 0.684 | ||
Lesser toes | 10.3 ± 1.1 | 10.8 ± 0.4 | 0.988 | ||
Maximum force (%BW) | |||||
Heel | 69.5 ± 15.2 | 67.1 ± 11.3 | 0.817 | ||
Midfoot | 30.3 ± 7.1 | 23.6 ± 7.4 | 0.43 | ||
1st MTPJ | 32.3 ± 7.1 | 26.5 ± 6.2 | 0.037* | ||
2nd MTPJ | 35.2 ± 9.1 | 30.3 ± 5.1 | 0.041* | ||
3rd-5th MTPJ | 17.7 ± 5.4 | 16.7 ± 4.9 | 0.843 | ||
Hallux | 14.3 ± 6.5 | 13.5 ± 5.6 | 0.901 | ||
Lesser toes | 12.0 ± 4.7 | 12.6 ± 3.2 | 0.973 | ||
Plantar pressure (kPa) | |||||
Heel | 252.9 ± 52.5 | 243.7 ± 52.5 | 0.581 | ||
Midfoot | 132.8 ± 28.3 | 116.5 ± 30.0 | 0.031* | ||
1st MTPJ | 295.1 ± 100.4 | 224.3 ± 62.4 | 0.024* | ||
2nd MTPJ | 273.8 ± 103.9 | 244.6 ± 56.1 | 0.183 | ||
3rd-5th MTPJ | 156.1 ± 43.1 | 157.9 ± 49.3 | 0.981 | ||
Hallux | 231.9 ± 77.6 | 219.6 ± 79.4 | 0.531 | ||
Lesser toes | 139.4 ± 49.4 | 142.9 ± 44.9 | 0.801 |